Thymosin (e.g., Thymosin (alpha 1, Thymosin Beta 4, Etc.) Or Derivative Patents (Class 514/12.9)
-
Patent number: 11433080Abstract: A method of treating a subject in need of anti-coronavirus treatment by providing a prophylactic or therapeutic treatment which includes an antiviral effective amount of an Azelastine compound, where the antiviral effective amount is 0.1-500 ?g per dose. An Azelastine compound can also be used as an antiviral substance in a medicinal product for treating a biological surface to prevent coronavirus infection and/or coronavirus spread, or as a viral disinfectant.Type: GrantFiled: December 27, 2021Date of Patent: September 6, 2022Assignee: CEBINA GMBHInventors: Eszter Nagy, Gabor Nagy, Valeria Szijarto, Robert Konrat
-
Patent number: 9249185Abstract: The present invention relates to a peptide promoting angiogenesis and novel use thereof. More particularly, the invention relates to peptides promoting angiogenesis, and the use of the peptide for promoting angiogenesis and preventing or treating angiogenesis-related disease. The peptide of the present invention have an excellent effect on promoting angiogenesis. Accordingly, it is useful for preventing or treating angiogenesis-related disease and for preparing regeneration of skin flap, wound and burn healing, implantation of artificial-skin and preparation of blood vessels for transplantation.Type: GrantFiled: March 25, 2011Date of Patent: February 2, 2016Assignees: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, SOOKMYUNG WOMEN'S UNIVERSITY, IL-YANG PHARM. CO., LTD, SAMSUNG LIFE WELFARE FOUNDATIONInventors: Sa Ik Bang, Juah Son, Sang Yoon Kim, Jeong Min Park, Yoo Rim Park, Ha Rum Lee, Sun Young Yoon, Dae Ho Cho
-
Publication number: 20150037281Abstract: The present invention relates to novel Prothymosin Alpha (ProT?) variants that are capable of inducing cell-mediated immune responses. These variants lack a nuclear localization signal and the proliferative oncogenic activity previously attributed to ProT?. The variants of the invention are used in methods of treating, for example, viral infections, bacterial infections, fungal infections, cancer, ischemia and myeloproliferative blood disorders. Administration of a ProT? variant to a subject in a therapeutically effective amount treats the infection or disease.Type: ApplicationFiled: March 1, 2013Publication date: February 5, 2015Applicant: Icahn School of Medicine at Mount SinaiInventors: Arevik Mosoian, Avelino Teixeira
-
Publication number: 20150031617Abstract: The present invention provides methods for preventing or treating purulent rhinosinusitis. These methods include administering a composition comprising thymosin alpha 1 to a subject.Type: ApplicationFiled: March 8, 2013Publication date: January 29, 2015Inventor: Hemmo A. Drexhage
-
Patent number: 8716012Abstract: The present invention provides methods of vaccination as well as pharmaceutical combinations and kits for enhancing vaccine effectiveness, including for immunodeficient or immunecompromised patients, including non-responders and low-responders to vaccination. As disclosed herein, the invention relates to administering a vaccine and a regimen of thymosin alpha peptide so as to provide higher antibody titers, speed the development of such antibody titers, and/or to provide for a longer duration of such antibody titers, thereby providing a greater protective effect. In another aspect, the invention allows for reducing a vaccine dose, such as an influenza vaccine dose, by administration of a thymosin peptide regimen.Type: GrantFiled: May 10, 2010Date of Patent: May 6, 2014Assignee: Sciclone Pharmaceuticals, Inc.Inventor: Cynthia W. Tuthill
-
Publication number: 20140065102Abstract: It is disclosed a method for the treatment of HBV infection or HBV/HDV co-infection, the method comprising administering to a subject in need of treatment a first pharmaceutically acceptable agent that removes the hepatitis B surface antigen from the blood and a second pharmaceutically acceptable agent which stimulates immune function.Type: ApplicationFiled: May 17, 2013Publication date: March 6, 2014Inventors: Michel BAZINET, Andrew VAILLANT
-
Publication number: 20130309201Abstract: It is disclosed a pharmaceutical composition containing an oligonuclelotide chelate complex and at least one polypeptide or pegylated polypeptide. The present disclosure also describes additional pharmaceutical compositions and methods for the treatment of diseases including viral infections.Type: ApplicationFiled: May 17, 2013Publication date: November 21, 2013Inventors: Michel BAZINET, Andrew VAILLANT
-
Publication number: 20130177531Abstract: This invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof wherein C* represents a diastereomeric carbon comprising a mixture of R and S isomers wherein the R isomer is greater than 50% of the mixture.Type: ApplicationFiled: February 28, 2013Publication date: July 11, 2013Applicant: Vertex Pharmaceuticals IncorporatedInventor: Vertex Pharmaceuticals Incorporated
-
Publication number: 20130130986Abstract: This disclosure provides modified cytosine deaminases(CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders. It further provides use of such modified CDs with a thymosin-alpha-1 polypeptide in the treatment of disease and disorders.Type: ApplicationFiled: March 29, 2011Publication date: May 23, 2013Applicant: TOCAGEN INC.Inventors: Harry E. Gruber, Douglas J. Jolly, Omar Perez, Derek G. Ostertag, Joan M. Robbins
-
Publication number: 20130078218Abstract: The invention provides methods for treating hepatitis C viral infections and related viral infections, as well as compounds and compositions that are useful for treating such infections.Type: ApplicationFiled: March 26, 2012Publication date: March 28, 2013Inventors: Yarlagadda S. Babu, Pooran Chand, Minwan Wu, Pravin L. Kotian, V. Satish Kumar, Tsu-Hsing Lin, Yahya El-Kattan, Ajit K. Ghosh
-
Patent number: 8389680Abstract: A method for treating a human infected with Aspergillus by using thymosin alpha 1 as an immuno-stimulator in activating dendritic cells. The method is particularly useful in preventing an infection by Aspergillus in an immuno-compromised host being treated with a bone marrow transplantation.Type: GrantFiled: May 29, 2012Date of Patent: March 5, 2013Assignee: SciClone Pharmaceuticals, Inc.Inventors: Guido Rasi, Enrico Garaci, Francesco Bistoni, Luigina Romani, Paolo Di Francesco
-
Publication number: 20120165259Abstract: The invention provides a method of ameliorating a blood-brain barrier disorder, as well as a method of treating a disease accompanied by a blood-brain barrier disorder and a method of treating a cerebral ischemic disease, by administering a prothymosin ?, or a protein or polypeptide possessing the same function as the prothymosin ?. The invention also provides polypeptides useful in the context of the aforesaid methods.Type: ApplicationFiled: August 9, 2010Publication date: June 28, 2012Applicant: NAGASAKI UNIVERSITYInventor: Hiroshi Ueda
-
Patent number: 8207294Abstract: A method for treating a human infected with Aspergillus by using thymosin alpha 1 as an immuno-stimulator in activating dendritic cells. The method is particularly useful in preventing an infection by Aspergillus in an immuno-compromised host being treated with a bone marrow transplantation.Type: GrantFiled: March 29, 2004Date of Patent: June 26, 2012Assignee: SciClone Pharmaceuticals, Inc.Inventors: Guido Rasi, Enrico Garaci, Francesco Bistoni, Luigina Romani, Paolo Di Francesco
-
Publication number: 20120071411Abstract: A composition including a peptide agent including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2], a conservative variant thereof, or a stimulating agent that stimulates production of an LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2] peptide, or a conservative variant thereof, the composition including at least one amino acid stabilizing agent or lyophilization bulking agent, the composition being in lyophilized form, or in a form capable of being lyophilized.Type: ApplicationFiled: August 26, 2011Publication date: March 22, 2012Applicant: REGENERX BIOPHARMACEUTICALS, INC.Inventors: David CROCKFORD, Allan L. GOLDSTEIN
-
Publication number: 20120065132Abstract: A method of treatment for treating, preventing, inhibiting or reducing tissue deterioration, injury or damage due to congestive heart failure disease, or for restoring tissue adversely affected by said disease, in a subject, includes administering to a subject an effective amount of a composition including a peptide agent including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2], a conservative variant thereof, or a peptide agent that stimulates production of an LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2] peptide, or a conservative variant thereof, in the tissue.Type: ApplicationFiled: September 9, 2011Publication date: March 15, 2012Applicant: REGENERX BIOPHARMACEUTICALS, INC.Inventor: David CROCKFORD
-
Publication number: 20120014914Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt, or mixtures thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.Type: ApplicationFiled: September 21, 2011Publication date: January 19, 2012Applicant: Vertex Pharmaceuticals IncorporatedInventors: Luc J. Farmer, Robert B. Perni, Govinda Rao Bhisetti, Keith P. Wilson
-
Publication number: 20120009260Abstract: A therapeutic or bioeffecting film delivery system which includes nanoparticles having actives bound to or associated with the nanoparticles and which when administered allow the active to perform a therapeutic or bioeffecting function.Type: ApplicationFiled: June 10, 2011Publication date: January 12, 2012Inventors: Alexander M. Schobel, Garry L. Myers, Keith Joseph Kendall, Thomas Rademacher, Jan Mous, Justin N. W. Barry, Phillip Williams, Africa Garcia Barrientos
-
Publication number: 20110318401Abstract: The present invention provides a method of treating a leg ulcer comprising contacting the leg ulcer with a collagen biofabric. The leg ulcer may be a venous, arterial, diabetic or decubitus (pressure) ulcer. The invention further provides kits comprising one or more pieces of collagen biofabric for the treatment of a leg ulcer.Type: ApplicationFiled: April 18, 2011Publication date: December 29, 2011Inventors: Robert J. Hariri, Janice M. Smiell
-
Patent number: 8080522Abstract: Polyethylene glycol modifications of thymosin alpha 1 (T&agr; 1-PEGs), their preparation process, the medicine composition containing them, and their application in the medicine for preventing and treating diseases related with immune deficiency and hypoimmunity, including hepatitis B, hepatitis C, hepatoma, malignant melanoma, non-small cell lung cancer, SARS, and AIDS etc.Type: GrantFiled: November 11, 2006Date of Patent: December 20, 2011Assignee: Institute of Pharmacology and Toxicology Academy of Military Mecical Sciences, P.L.A., ChinaInventors: Keliang Liu, Jiankun Qie, Jinbo Ma, Jianquan Zheng, Sijian Dong, Wenxia Zhou, Chunhui Qi
-
Publication number: 20110281802Abstract: Composition for treatment and prevention of human hair loss and/or hair greying, comprising an effective amount of thymic peptides of the family thymulin, thymosin alpha-1 and thymosin beta-4 and pharmaceutical excipient, diluent or carrier. Method and pharmaceutical composition for treatment and prevention of balding, hair loss, and alopecia.Type: ApplicationFiled: December 1, 2008Publication date: November 17, 2011Applicant: Immudiagnostik AGInventors: Franz Paul Armbruster, Ralf Paus, Dorothee Langan
-
Patent number: 8022036Abstract: It is described the use of thymosin alpha 1 for preparing a medicament useful for the prevention or treatment of graft-versus-host disease or graft rejection reactions in organ transplantation, in a mammal subject, in which the cells, tissues or organs for transplant is selected from the group comprising: stem cells, hematopoietic stem cells, bone marrow, heart, liver, kidney, lung, pancreas, small intestine, cornea or skin.Type: GrantFiled: November 17, 2008Date of Patent: September 20, 2011Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Luigina Romani, Francesco Bistoni, Enrico Garaci
-
Publication number: 20110172155Abstract: Peptide fragments having amino acid sequences corresponding to portions of a thymosin beta 4, a thymosin beta and/or a thymosin beta 15 amino acid sequence are provided, as well as methods of treatment utilizing same.Type: ApplicationFiled: March 13, 2009Publication date: July 14, 2011Applicant: REGENERX BIOPHARMACEUTICALS, INC.Inventors: David Crockford, Christian B. Allan, Gabriel Sosne
-
Publication number: 20110166071Abstract: The invention relates to a method for obtaining thymosins and/or the pharmaceutically acceptable salts thereof by means of solid-phase synthesis on polymeric supports, which comprises the steps of linearly synthesizing the thymus-derived peptides in solid phase, incorporating at least one Thr or Ser in the sequence, in pseudoproline dipeptide form, obtaining the thymosins by treating the peptidyl resin with trifluoroacetic acid, and purifying the thymosins by RP-HPLC. The present invention also protects the isolated and/or purified compound obtained by means of said method and also the use thereof in the preparation of a medicinal product.Type: ApplicationFiled: April 25, 2007Publication date: July 7, 2011Inventors: Jimena Fernandez Carneado, Berta Ponsati Obiols, Javier Clemente Rodriguez, Raimon Rubires Ferrer, Sergi Pavon Fernandez
-
Publication number: 20110165120Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease.Type: ApplicationFiled: February 28, 2011Publication date: July 7, 2011Applicant: Vertex Pharmaceuticals IncorporatedInventors: Kevin M. Cottrell, John Maxwell, Qing Tang, Anne-Laure Grillot, Arnaud Le Tiran, Emanuele Perola
-
Publication number: 20110144020Abstract: Microbial infections including anthrax infection, and gastrointestinal disorders, are treated or prevented by administration of an actin-sequestering peptide including amino acid sequence LKKTET, such as Thymosin ?4, an isoform of Thymosin ?4, oxidized Thymosin ?4, or T?4 sulfoxide.Type: ApplicationFiled: April 9, 2008Publication date: June 16, 2011Applicant: REGENERX BIOPHARMACEUTICALS, INC.Inventors: Allan L. GOLDSTEIN, Jack FINKELSTEIN, JR.
-
Publication number: 20110135596Abstract: A transmembrane fusion protein including ubiquitin or a ubiquitin-like protein, a membrane translocation sequence linked to the C-terminus of the ubiquitin or ubiquitin-like protein, and a biologically active molecule linked to the C-terminus of the membrane translocation sequence is disclosed herein. A polynucleotide encoding the transmembrane fusion protein, a recombinant expression vector including the polynucleotide sequence, a cell transformed by the recombinant expression vector, and a method of delivering the biologically active molecule into a cell using the transmembrane fusion protein are also disclosed.Type: ApplicationFiled: December 3, 2010Publication date: June 9, 2011Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Jae-il LEE, Tae-soo LEE, Young-sun LEE
-
Publication number: 20100317583Abstract: Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and an antineoplastic heat shock apoptosis activator (HSAA) such as STA-4783 (and optionally an antineoplastic cytotoxic chemotherapeutic agent such as paclitaxel), and/or optionally one or more additional anti-melanoma agents.Type: ApplicationFiled: December 11, 2008Publication date: December 16, 2010Applicant: SciClone Pharmaceuticals, Inc.Inventors: Israel Rios, Cynthia W. Tuthill
-
Publication number: 20100311656Abstract: An alpha thymosin peptide is administered to a patient having, or at risk of a respiratory viral infection, coronavirus infection and/or SARS.Type: ApplicationFiled: June 16, 2010Publication date: December 9, 2010Applicant: SciClone Pharmaceuticals, Inc.Inventors: Alfred R. RUDOLPH, Cynthia W. TUTHILL
-
Publication number: 20100278934Abstract: A method of conserving and/or preparing an organ or tissue for transplant for a subject, includes administering to a subject, organ or tissue in need of such treatment an effective amount of a composition including a polypeptide agent including thymosin beta 4 (TB4), an isoform, analogue or derivative of TB4 having biological activity of TB4, an N-terminal variant of TB4 having biological activity of TB4, a C-terminal variant of TB4 having biological activity of TB4, LKKTET or a conservative variant thereof, LKKTNT or a conservative variant thereof, KLKKTET or a conservative variant thereof, LKKTETQ or a conservative variant thereof, TB4 sulfoxide, TB4ala, TB9, TB10, TB11, TB12, TB13, TB14, TB15, gelsolin, vitamin D binding protein (DBP), profilin, cofilin, adsevertin, propomyosin, fincilin, depactin, Dnasel, vilin, fragmin, severin, capping protein, ?-actinin or acumentin, or a stimulating agent that stimulates production of a polypeptide agent as described above, or a conservative variant thereof, in the orType: ApplicationFiled: August 6, 2007Publication date: November 4, 2010Applicant: Regenerx Biopharmaceuticals Inc.Inventors: Jack Finkelstein, JR., C. Neil Lyons
-
Publication number: 20100267637Abstract: Melanoma or a metastasis thereof is treated in a human patient in a combination therapy which includes administering a melanoma-treating combination to a human melanoma patient during a treatment regimen, the combination including an alpha thymosin peptide and a kinase inhibitor.Type: ApplicationFiled: December 12, 2008Publication date: October 21, 2010Applicant: SciClone Pharmaceuticals, Inc.Inventors: Israel Rios, Cynthia W. Tuthill